BALTIMORE--(EON: Enhanced Online News)--Cerecor Inc., a biopharmaceutical company developing neuroscience drugs that make a difference in underserved patient segments of common diseases, today announced that Blake Paterson, MD, CEO and Co-Founder, will present a corporate overview, highlighting CERC-301, an oral rapid-acting antidepressant in clinical development for treatment-resistant depression, and its COMT inhibitor platform for the treatment of the cognitive impairment observed in many different conditions at the 12th Annual BIO Investor Forum in San Francisco, CA. The presentation will take place on Wednesday, October 9, 2013, at 2pm PT.
Cerecor Inc. is a privately held biopharmaceutical company focused on the development and commercialization of prescription pharmaceuticals whose primary site of activity is in the human nervous system. The Company is developing first-in-class drugs where human proof-of-concept has been established for the target, the molecule, or both in conditions for which established biomarkers are available to facilitate development. Cerecor’s programs address the needs of underserved sub-segments of major diseases. Cerecor increases the probability of clinical success by employing specific trial methodologies that reduce placebo response rates and enhance efficacy signals. www.cerecor.com.